The antibacterial effect of nitric oxide against ESBL-producing uropathogenic E. coli is improved by combination with miconazole and polymyxin B nonapeptide

BMC Microbiology

Volumn 14, Issue 1, 2014, Pages

  Bang, Charlotte Sahlberg ^a   Kinnunen, Annica ^a   Karlsson, Marie ^a   Önnberg, Anna ^a,b   Söderquist, Bo ^a,b   Persson, Katarina ^a,c  

^a Örebro University   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

Author keywords

Extended spectrum lactamase; Nitric oxide; Polymyxin B nonapeptide; Uropathogenic E. coli

Indexed keywords

CEFOTAXIME; CEFTAZIDIME; CEFTIBUTEN; CIPROFLOXACIN; FLAVOHEMOGLOBIN; GENTAMICIN; HEMOGLOBIN; MECILLINAM; MICONAZOLE; NITRIC OXIDE; POLYMYXIN B NONAPEPTIDE; TRIMETHOPRIM; UNCLASSIFIED DRUG; IMIDAZOLE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL VIABILITY; BACTERIOSTASIS; BACTERIUM ISOLATE; CELL MEMBRANE PERMEABILITY; ENZYME INHIBITION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; GENE DELETION; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; BACTERIAL MEMBRANE; BACTERIUM ISOLATION; CONTROLLED STUDY; MEMBRANE PERMEABILITY; UROPATHOGENIC ESCHERICHIA COLI; WILD TYPE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DIHYDROPTERIDINE REDUCTASE; DRUG SYNERGISM; ESCHERICHIA COLI PROTEINS; HEMEPROTEINS; HUMANS; MICONAZOLE; MICROBIAL SENSITIVITY TESTS; NADH, NADPH OXIDOREDUCTASES; NANOPARTICLES; NITRIC OXIDE; POLYMYXIN B; UROPATHOGENIC ESCHERICHIA COLI;

BACTERIA (MICROORGANISMS);

EID: 84899073270     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-14-65     Document Type: Article

References (42)

1. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Fang FC, Nat Rev Microbiol 2004 2 10 820 832 10.1038/nrmicro1004 15378046
2. Nitric oxide synthase: an endogenous source of elevated nitrite in infected urine. Smith SD, Wheeler MA, Weiss RM, Kidney Int 1994 45 2 586 591 10.1038/ki.1994.76 7513034
3. Bacterial infection induces nitric oxide synthase in human neutrophils. Wheeler MA, Smith SD, Garcia-Cardena G, Nathan CF, Weiss RM, Sessa WC, J Clin Invest 1997 99 1 110 116 10.1172/JCI119121 9011564
4. A kinetic platform to determine the fate of nitric oxide in Escherichia coli. Robinson JL, Brynildsen MP, PLoS Comput Biol 2013 9 5 1003049 10.1371/journal.pcbi.1003049 23658508
5. Intravesical nitric oxide delivery for prevention of catheter-associated urinary tract infections. Carlsson S, Weitzberg E, Wiklund P, Lundberg JO, Antimicrob Agents Chemother 2005 49 6 2352 2355 10.1128/AAC.49.6.2352-2355.2005 15917532
6. Uropathogenic Escherichia coli and tolerance to nitric oxide: the role of flavohemoglobin. Svensson L, Marklund BI, Poljakovic M, Persson K, J Urol 2006 175 2 749 753 10.1016/S0022-5347(05)00144-8 16407044
7. Conditioning of uropathogenic Escherichia coli for enhanced colonization of host. Bower JM, Gordon-Raagas HB, Mulvey MA, Infect Immun 2009 77 5 2104 2112 10.1128/IAI.01200-08 19255192
8. Nitric oxide dioxygenase: an enzymic function for flavohemoglobin. Gardner PR, Gardner AM, Martin LA, Salzman AL, Proc Natl Acad Sci U S A 1998 95 18 10378 10383 10.1073/pnas.95.18.10378 9724711
9. New functions for the ancient globin family: bacterial responses to nitric oxide and nitrosative stress. Poole RK, Hughes MN, Mol Microbiol 2000 36 4 775 783 10.1046/j.1365-2958.2000.01889.x 10844666
10. Protection from nitrosative stress: a central role for microbial flavohemoglobin. Forrester MT, Foster MW, Free Radic Biol Med 2012 52 9 1620 1633 10.1016/j.freeradbiomed.2012.01.028 22343413
11. The flavohemoglobin of Escherichia coli confers resistance to a nitrosating agent, a "Nitric oxide Releaser," and paraquat and is essential for transcriptional responses to oxidative stress. Membrillo-Hernandez J, Coopamah MD, Anjum MF, Stevanin TM, Kelly A, Hughes MN, Poole RK, J Biol Chem 1999 274 2 748 754 10.1074/jbc.274.2.748 9873011
12. Role of flavohemoglobin in combating nitrosative stress in uropathogenic Escherichia coli-implications for urinary tract infection. Svensson L, Poljakovic M, Save S, Gilberthorpe N, Schon T, Strid S, Corker H, Poole RK, Persson K, Microb Pathog 2010 49 3 59 66 10.1016/j.micpath.2010.04.001 20399845
13. The X-ray structure of ferric Escherichia coli flavohemoglobin reveals an unexpected geometry of the distal heme pocket. Ilari A, Bonamore A, Farina A, Johnson KA, Boffi A, J Biol Chem 2002 277 26 23725 23732 10.1074/jbc.M202228200 11964402
14. Imidazole antibiotics inhibit the nitric oxide dioxygenase function of microbial flavohemoglobin. Helmick RA, Fletcher AE, Gardner AM, Gessner CR, Hvitved AN, Gustin MC, Gardner PR, Antimicrob Agents Chemother 2005 49 5 1837 1843 10.1128/AAC.49.5.1837-1843.2005 15855504
15. Binding of azole antibiotics to Staphylococcus aureus flavohemoglobin increases intracellular oxidative stress. Nobre LS, Todorovic S, Tavares AF, Oldfield E, Hildebrandt P, Teixeira M, Saraiva LM, J Bacteriol 2010 192 6 1527 1533 10.1128/JB.01378-09 20097858
16. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Pitout JD, Laupland KB, Lancet Infect Dis 2008 8 3 159 166 10.1016/S1473-3099(08)70041-0 18291338
17. Extended spectrum beta-lactamases (ESBL) in Escherichia coli and Klebsiella pneumoniae: trends in the hospital and community settings. Khanfar HS, Bindayna KM, Senok AC, Botta GA, J Infect Dev Ctries 2009 3 4 295 299 19759493
18. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Hoban DJ, Lascols C, Nicolle LE, Badal R, Bouchillon S, Hackel M, Hawser S, Diagn Microbiol Infect Dis 2012 74 1 62 67 10.1016/j.diagmicrobio.2012.05.024 22763019
19. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Bonnet R, Antimicrob Agents Chemother 2004 48 1 1 14 10.1128/AAC.48.1.1-14.2004 14693512
20. Antibiotics at the crossroads. Nathan C, Nature 2004 431 7011 899 902 10.1038/431899a 15496893
21. Molecular and phenotypic characterization of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases with focus on CTX-M in a low-endemic area in Sweden. Onnberg A, Molling P, Zimmermann J, Soderquist B, APMIS 2011 119 4-5 287 295 21492229
22. "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Keefer LK, Nims RW, Davies KM, Wink DA, Methods Enzymol 1996 268 281 293 8782594
23. Agents that increase the permeability of the outer membrane. Vaara M, Microbiol Rev 1992 56 3 395 411 1406489
24. Microbial responses to nitric oxide and nitrosative stress: growth, "omic," and physiological methods. Pullan ST, Monk CE, Lee L, Poole RK, Methods Enzymol 2008 437 499 519 18433644
25. Integrated network analysis identifies nitric oxide response networks and dihydroxyacid dehydratase as a crucial target in Escherichia coli. Hyduke DR, Jarboe LR, Tran LM, Chou KJ, Liao JC, Proc Natl Acad Sci U S A 2007 104 20 8484 8489 10.1073/pnas.0610888104 17494765
26. Study on in-vitro susceptibility of ESBL-positive Escherichia coli isolated from urine specimens. Grandesso S, Sapino B, Mazzucato S, Alessandrini R, Solinas M, Gion M, Infez Med 2010 18 3 162 168 20956871
27. Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Vanden Bossche H, Marichal P, Gorrens J, Coene MC, Willemsens G, Bellens D, Roels I, Moereels H, Janssen PA, Mycoses 1989 32 Suppl 1 35 52 2561184
28. Synergy of nitric oxide and azoles against Candida species in vitro. McElhaney-Feser GE, Raulli RE, Cihlar RL, Antimicrob Agents Chemother 1998 42 9 2342 2346 9736560
29. Synergism of the antimicrobial agents miconazole, bacitracin and polymyxin B. Cornelissen F, Van den Bossche H, Chemotherapy 1983 29 6 419 427 10.1159/000238230 6317296
30. Role of the cell envelope in the antibacterial activities of polymyxin B and polymyxin B nonapeptide against Escherichia coli. Sahalan AZ, Dixon RA, Int J Antimicrob Agents 2008 31 3 224 227 10.1016/j.ijantimicag.2007.10.005 18083010
31. Synergistic effects of miconazole and polymyxin B on microbial pathogens. Pietschmann S, Hoffmann K, Voget M, Pison U, Vet Res Commun 2009 33 6 489 505 10.1007/s11259-008-9194-z 19085068
32. Miconazole induces changes in actin cytoskeleton prior to reactive oxygen species induction in yeast. Thevissen K, Ayscough KR, Aerts AM, Du W, De Brucker K, Meert EM, Ausma J, Borgers M, Cammue BP, Francois IE, J Biol Chem 2007 282 30 21592 21597 10.1074/jbc.M608505200 17553796
33. Morphological analysis of the antimicrobial action of nitric oxide on gram-negative pathogens using atomic force microscopy. Deupree SM, Schoenfisch MH, Acta Biomater 2009 5 5 1405 1415 10.1016/j.actbio.2009.01.025 19250890
34. The effect of nitric oxide on adherence of P-fimbriated uropathogenic Escherichia coli to human renal epithelial cells. Svensson L, Save S, Persson K, BJU Int 2010 105 12 1726 1731 19863519
35. Catheter-associated and nosocomial urinary tract infections: antibiotic resistance and influence on commonly used antimicrobial therapy. Milan PB, Ivan IM, Int Urol Nephrol 2009 41 3 461 464 10.1007/s11255-008-9468-y 18787972
36. Slow release of nitric oxide from charged catheters and its effect on biofilm formation by Escherichia coli. Regev-Shoshani G, Ko M, Miller C, Av-Gay Y, Antimicrob Agents Chemother 2010 54 1 273 279 10.1128/AAC.00511-09 19884372
37. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. Rogers BA, Sidjabat HE, Paterson DL, J Antimicrob Chemother 2011 66 1 1 14 10.1093/jac/dkq415 21081548
38. The emergence and dissemination of CTX-M-producing Escherichia coli sequence type 131 causing community-onset bacteremia in Israel. Karfunkel D, Carmeli Y, Chmelnitsky I, Kotlovsky T, Navon-Venezia S, Eur J Clin Microbiol Infect Dis 2013 32 4 513 521 10.1007/s10096-012-1765-9 23117265
39. Colistin: new lessons on an old antibiotic. Yahav D, Farbman L, Leibovici L, Paul M, Clin Microbiol Infect 2012 18 1 18 29 10.1111/j.1469-0691.2011. 03734.x 22168320
40. Potential application of gaseous nitric oxide as a topical antimicrobial agent. Ghaffari A, Miller CC, McMullin B, Ghahary A, Nitric Oxide 2006 14 1 21 29 10.1016/j.niox.2005.08.003 16188471
41. Susceptibility of Gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Friedman A, Blecher K, Sanchez D, Tuckman-Vernon C, Gialanella P, Friedman JM, Martinez LR, Nosanchuk JD, Virulence 2011 2 3 217 221 10.4161/viru.2.3.16161 21577055
42. A nitric oxide-inducible lactate dehydrogenase enables Staphylococcus aureus to resist innate immunity. Richardson AR, Libby SJ, Fang FC, Science 2008 319 5870 1672 1676 10.1126/science.1155207 18356528